VivoSeq
Other

General Anaesthesia

2

Pipeline Programs

4

Active Trials

2

Companies Involved

General Anaesthesia is an early-stage landscape with 2 programs across 2 companies. The most active players are Fresenius Kabi Oncology Ltd., AbbVie. 2 therapies are approved.

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

6/100

Mech. Concentration

50/100

Completion Rate

100/100

Attrition Rate

0/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs

Trial Status

27

clinical trials

Completed20 · 74%
Unknown status3 · 11%
Recruiting3 · 11%
Not yet recruiting1 · 4%

Trial Activity

27 trials

Neuroplasticity Induced by General Anaesthesia
Completed··N/A·NCT04125121·20 enrolled
Dexmetomidine in Children Undergoing General Anaesthesia
Completed··N/A·NCT03923075·60 enrolled
Spinal Anaesthesia vs. General Anaesthesia for THA, TKA and UKA
Completed··Phase 4·NCT05706844·222 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)